Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | MPL | P40238 | 2/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453079 | 1.00 | PDE2A (0.46) | PDE2AIDO1MPLTAS2R14PTPN5 | |
| SCHEMBL27858715 | 0.83 | KDM1A (0.39) | PDE2AKDM1AKCNH2KDM1B | |
| SCHEMBL16046268 | 0.82 | KDM1A (0.36) | PDE2AIDO1KDM1AKCNH2KDM1B | |
| SCHEMBL5350038 | 0.82 | KDM1A (0.36) | PDE2AIDO1KDM1AKCNH2KDM1B | |
| SCHEMBL29762963 | 0.81 | IDO1 (0.44) | PDE2AIDO1MPLTAS2R14PTPN5 | |
| SCHEMBL283936 | 0.81 | IDO1 (0.44) | PDE2AIDO1MPLTAS2R14PTPN5 | |
| SCHEMBL31082039 | 0.80 | PDE2A (0.41) | PDE2AIDO1MPLPTPN5KDM1A | |
| SCHEMBL7863398 | 0.80 | PTPN5 (0.41) | TAS2R14PTPN5MAPTXBP1NPSR1 | |
| SCHEMBL29637726 | 0.80 | PTPN5 (0.41) | TAS2R14PTPN5MAPTXBP1NPSR1 | |
| SCHEMBL1104683 | 0.79 | ALDH1A1 (0.41) | KDM1AKCNH2KDM1BMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 477 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3543319-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | Johnson Matthey Public Limited Company (GB) | 2019-09-25 | — | — | EP | claimed |
| US-20140120626-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2014-05-01 | — | — | US | claimed |
| EP-2707465-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | Johnson Matthey Public Limited Company (GB) | 2014-03-19 | — | — | EP | claimed |
| WO-2012153132-A1 | METHOD OF MARKING HYDROCARBON LIQUIDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2012-11-15 | — | — | WO | claimed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260124197-A1 | NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-05-07 | — | — | US | disclosed |
| WO-2026089992-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12577257-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250376484-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12492181-B2 | Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-0453503-B1 | PHENYL NAPHTHALENES HAVING LIQUID CRYSTALLINE PROPERTIES | SECR DEFENCE BRIT (GB) | 1995-03-22 | — | — | EP | disclosed |
| US-5252253-A | Phenyl naphthalenes having liquid crystalline properties | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1993-10-12 | — | — | US | disclosed |
| EP-0453503-A1 | PHENYL NAPHTHALENES HAVING LIQUID CRYSTALLINE PROPERTIES. | SECR DEFENCE BRIT (GB) | 1991-10-30 | — | — | EP | disclosed |
| WO-1990008119-A1 | PHENYL NAPHTHALENES HAVING LIQUID CRYSTALLINE PROPERTIES | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1990-07-26 | — | — | WO | disclosed |
| EP-0122693-B1 | ANTIFUNGAL DI(AZOLYL)PROPANOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-07-08 | — | — | EP | disclosed |
| US-4625036-A | Antifungal azole compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-11-25 | — | — | US | disclosed |
| EP-0145314-A1 | Antifungal triazole compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-06-19 | — | — | EP | disclosed |
| EP-0122693-A1 | Antifungal di(azolyl)propanol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | PDE2A 1640/4885IDO1 2735/4885MPL 3935/4885 |
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | PDE2A 1219/4885IDO1 3544/4885MPL 1503/4885 |
| US-20260124197-A1 | NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YAP1, RCC1, YES1 | PDE2A 3751/4885IDO1 1966/4885MPL 4378/4885 |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PDE2A 2095/4885IDO1 2482/4885MPL 3225/4885 |
| US-20250376484-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | PDE2A 895/4885IDO1 2702/4885MPL 2256/4885 |
| US-12492181-B2 | Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC1R, MC3R, MC2R | PDE2A 1028/4885IDO1 1013/4885MPL 150/4885 |
| US-12577257-B2 | Heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 | PDE2A 1450/4885IDO1 3471/4885MPL 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.